![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
This company has very interesting products in development. They have a library of Chinese medicine extracts which they are screening for treatment of diseases from AIDS to cancer. If you think this sounds somewhat farfetched, consider that they are collaborating with the National Cancer Institute (Bethesda, MD) - their science is sound. Their lead product, PN355, a tyrosine kinase inhibitor, interferes with intracellular signalling within T-cells, and is in Phase I trials for combatting HIV-1. They are also collaborating with the National Cancer Insitute to develop PN355 and related compounds for treating cancer. The stock is low now, about 1 1/2. Consider that the 52-week high was 8, and the low was 15/16. The stock made a recent run into the mid 2's, and I think it may make another run soon. I have heard from my broker that the manager of the Health Sciences Fund bought a lot of this stock last week at 1 7/8. At 1 1/2, I think it is a good buy. Of course, it is very risky, but if any positive Phase II results are announced, the price could skyrocket. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |